Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel, Juergen Barth, Christina Balser et al.|The Lancet Oncology|2015

Cited by 155